What an excellent report. Many thanks for bringing it to our attention. Interesting that their DCF valuation attributes a 55% chance of passing Phase III trials for OA, and 40.5% chance for MPS.
Some people here on HC have predicted the chance of success to be much higher for OA which, if true, may imply significant upside to the current price target of $4.31 per share suggested in the report.
research reports and media, page-431
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 29.5¢ | $86.19K | 286.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70151 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18600 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |